Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists~* Proof of a malignancy harboring a NTRK fusion~* Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 and a life expectancy of at least 3 months~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* Patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible~* Clinically significant active cardiovascular disease or history of myocardial infarction~* Active uncontrolled systemic bacterial, viral, or fungal infection~* Current treatment with a strong CYP3A4 inhibitor or inducer~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tumor patients_Dose 1 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
- Tumor patients_Dose 2 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
- Tumor patients_Dose 3 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
- Tumor patients_Dose 4 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
- Tumor patients_Dose 5 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
- Tumor patients_Dose 6 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
- Tumor patients_Expansion (Type: EXPERIMENTAL): Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part.

Based on this trial design, predict the completion outcome and termination type (if applicable).